Fabry Disease Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Fabry Disease pipeline constitutes 18+ key companies continuously working towards developing 18+ Fabry Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Fabry Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fabry Disease Market.
The Fabry Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Fabry Disease Pipeline Report:
• Fabry Disease Companies across the globe are diligently working toward developing novel Fabry Disease treatment therapies with a considerable amount of success over the years.
• Fabry Disease companies working in the treatment market are Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 Therapeutics, Amicus Therapeutics, Sigilon Therapeutics, and others are developing therapies for the Fabry Disease treatment
• Emerging Fabry Disease therapies such as Venglustat, Pegunigalsidase alfa, 4D 310, and others are expected to have a significant impact on the Fabry Disease market in the coming years.
• In July 2024, Sanofi announced a Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
• Sangamo Therapeutics, Inc.: ST-920 (Isaralgagene Civaparvovec): Sangamo announced alignment with the FDA on an accelerated approval pathway for ST-920 in October 2024. The Phase 1/2 STAAR study is ongoing, and the company expects to submit a Biologics License Application (BLA) in the second half of 2025.
• uniQure: AMT-191: Patient enrollment in the clinical trial for AMT-191, a gene therapy candidate for Fabry Disease, began in the first half of 2024. The Phase 1/2 trial is evaluating the safety and efficacy of this investigational therapy.

Fabry Disease Overview
Fabry Disease is a rare genetic disorder that prevents the body from making an enzyme called alpha-galactosidase A. This enzyme is responsible for breaking down a type of fat called globotriaosylceramide (Gb3 or GL-3) into building blocks that the body's cells can use. Fabry Disease can have many symptoms because it affects cells throughout the body. The symptoms include: Chronic pain - usually a burning or tingling sensation - in the hands and feet, Clusters of small, dark red spots in various locations on the skin, Opaque corneas, resulting in cloudy-looking eyes and problems with eyesight, Ringing in the ears, and hearing loss. Fabry Disease is caused by a mutation of the GLA gene, which encodes for the alpha-galactosidase A enzyme. The mutation usually makes the enzyme unable to function, although in mild cases, it may function to some degree. The disease is inherited in an X-linked dominant manner, which means that the gene involved is situated on the X chromosome.

Get a Free Sample PDF Report to know more about Fabry Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Fabry Disease Route of Administration
Fabry Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.

Fabry Disease Molecule Type
Fabry Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Fabry Disease Pipeline Therapeutics Assessment
• Fabry Disease Assessment by Product Type
• Fabry Disease By Stage and Product Type
• Fabry Disease Assessment by Route of Administration
• Fabry Disease By Stage and Route of Administration
• Fabry Disease Assessment by Molecule Type
• Fabry Disease by Stage and Molecule Type

DelveInsight's Fabry Disease Report covers around 18+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Fabry Disease product details are provided in the report. Download the Fabry Disease pipeline report to learn more about the emerging Fabry Disease therapies @ https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Fabry Disease Pipeline Analysis:
The Fabry Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Fabry Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fabry Disease Treatment.
• Fabry Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Fabry Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fabry Disease market.

Download Sample PDF Report to know more about Fabry Disease drugs and therapies- https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Fabry Disease Pipeline Drug Insight
• Coverage: Global
• Key Fabry Disease Companies: Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, Sangamo Therapeutics, 4D Molecular Therapeutics, Resverlogix Corp, AVROBIO, Freeline Therapeutics, Ozmosis Research Inc., CellGenTech, Inc., uniQure, Codexis, Canbridge, Eleva GmbH, MP6 Therapeutics, Amicus Therapeutics, Sigilon Therapeutics, and others.
• Key Fabry Disease Therapies: Venglustat, Pegunigalsidase alfa, 4D 310, and others.
• Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers

Request for Sample PDF Report for Fabry Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Fabry Disease Report Introduction
2. Fabry Disease Executive Summary
3. Fabry Disease Overview
4. Fabry Disease- Analytical Perspective In-depth Commercial Assessment
5. Fabry Disease Pipeline Therapeutics
6. Fabry Disease Late Stage Products (Phase II/III)
7. Fabry Disease Mid Stage Products (Phase II)
8. Fabry Disease Early Stage Products (Phase I)
9. Fabry Disease Preclinical Stage Products
10. Fabry Disease Therapeutics Assessment
11. Fabry Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Fabry Disease Companies
14. Fabry Disease Key Products
15. Fabry Disease Unmet Needs
16 . Fabry Disease Market Drivers and Barriers
17. Fabry Disease Future Perspectives and Conclusion
18. Fabry Disease Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.